EVO
Evotec SE Sponsored ADR · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website evotec.com
- Employees(FY) 5086
- ISIN US30050E1055
Performance
+1.52%
1W
-26.61%
1M
-30.61%
3M
-42.66%
6M
-54.39%
YTD
-50.46%
1Y
Profile
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer; Lilly; Almirall; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Janseen Biotech; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals, as well as a strategic partnership with Dewpoint Therapeutics to advance oncology pipeline programs of condensate modifying therapeutics to investigational new drug applications and a licensing agreement with Glycotope GmbH to develop next generation immune cell engaging bispecifics for various potential indications, including solid tumors The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
Investment Analysis Report: EVO
Overview
EVO is a company operating in the Health Technology sector, specifically in the Pharmaceuticals: Major industry. The company has a market capitalization of $2.61 billion. In this report, we will conduct a comprehensive analysis of EVO's financial statements over the past three years to evaluate its financ...
Technical Analysis of EVO 2024-05-10
Overview:
In analyzing the technical indicators for EVO stock over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key indicators, we aim to offer valuable insights and predictions for potentia...
Recent News & Updates
- 2024-05-01 21:00
3 Growth Stocks to Buy at 52-Week Lows(Investorplace)
- 2024-04-30 02:50
- 2024-04-29 14:50
- 2024-04-26 09:56
Analyst Report: Evotec SE(Morningstar Research)
- 2024-04-26 02:29
- 2024-04-25 00:26
Evotec Full Year 2023 Earnings: EPS Misses Expectations(Simply Wall St.)
- 2024-04-24 23:13
Analyst Report: Evotec SE(Morningstar Research)
- 2024-04-24 01:20
- 2024-04-24 01:08
- 2024-04-23 15:00
- 2024-04-23 13:20
- 2024-04-23 13:20
- 2024-04-23 03:00
- 2024-04-18 15:06
- 2024-04-18 07:45
- 2024-04-17 19:45
- 2024-04-17 15:04
- 2024-04-17 01:50
- 2024-04-16 21:15
- 2024-04-16 13:50
- 2024-04-12 10:55
Health Care Roundup: Market Talk(The Wall Street Journal)
- 2024-03-06 01:50
- 2024-03-05 12:50
- 2024-02-07 02:00
- 2024-02-06 13:00
- 2024-01-22 11:04
Evotec SE: Invitation to Conference Call(NewMediaWire)
- 2024-01-22 02:00
Evotec SE: Invitation to Conference Call(ACCESSWIRE)
- 2024-01-21 13:00
Evotec SE: Invitation to Conference Call(Accesswire)
- 2024-01-10 09:45
- 2024-01-09 20:45
Page 1 of 5
previousnext